Tangelo
The Tangleo clinical trial, sponsored by Hoffman La Roche is now open. This is a study of the safety and tolerability of RO7248824 in children with Angelman syndrome. Currently, the study is taking place in multiple locations world-wide.
See current and future locations here.
See current and future locations here.
Participant Requirements
Below is a preliminary list of inclusion criteria:
Inclusion Criteria
- Diagnosis of Angelman syndrome
- Between 1 and 12 years old
- Stable medical status for 4 weeks prior to screening visit
- Ability to tolerate blood draws
- Able to undergo LP and IT injection, under sedation or anesthesia 3 times during an 8-week period
See the full list of Eligibility Criteria on the clinical trials website.
More Information and Screening Enrollment
Find more information on the Roche website.
Questions about this study and enrollment interest can be directed to:
888-662-6728 (U.S. and Canada) or global-roche-genentech-trials@gene.com
Reference Study ID Number: BP41674
The Angelman Syndrome Foundation does not endorse any clinical trial or study, but provides information to the AS community for its own consideration.